OmniComm is a developer of a web-based technology in order to improve the delivery of information and streamline the clinical trial process. OmniComm’s remote data entry system, Trialmaster(R), gathers and checks the information for errors, then transmits that data via the Internet until the completion of a trial.
OmniComm’s expertise on the front end of the clinical trial process, brings a critical service to International Pharmaceutical Research, helping to identify physician investigators and their patients to participate and enroll in trials, through our medical portal, WebIPA(SM), said Dr David Ginsberg, OmniComm’s CEO, president, and author of The Investigator’s Guide to Clinical Research.
International Pharmaceutical Research’s expertise comes to play in the analysis of data to determine the results of a clinical trial, said Richard J. Marcel, CEO and president of IPR in a company statement. IPR has vast experience in submitting those results to the FDA for approval. This alliance builds upon a shared vision for the future of clinical research-speed through technology and accuracy through clean, reliable data, he added.
Together our companies bring an exciting new synergy to the clinical research process, we forge a powerful compound, said Dr Ginsberg, The result is that both clinical research and the public are better served in the end.
